FDA Grants Myeloma Therapy Fast Track Designation
What happened
The FDA has granted both Regenerative Medicine Advanced Therapy and Fast Track designations to CT103A (equecabtagene autoleucel). The designations are intended to accelerate the development and review of the therapy for relapsed or refractory multiple myeloma.
Why it matters
- The therapy, equecabtagene autoleucel, is a CAR T-cell therapy, which involves extracting a patient's own T-cells (a type of immune cell) and genetically engineering them to recognize and attack cancer cells. These modified cells are then infused back into the patient. - This specific therapy works by targeting the B-cell maturation antigen (BCMA), a protein found in high levels on the surface of multiple myeloma cells. - In the key clinical study, called FUMANBA-1, the therapy demonstrated a 96% overall response rate among 101 evaluable patients with relapsed or refractory multiple myeloma. Of those patients, 95% achieved minimal residual disease (MRD) negativity, meaning traces of cancer were undetectable. - The development of the Chimeric Antigen Receptor (the "CAR" in CAR-T) is a key role for computational biologists and bioinformaticians, who use large datasets to help identify unique protein targets on cancer cells to ensure the therapy is both effective and spares healthy tissue. - The human testing of such therapies is managed by patient-facing professionals like clinical research coordinators and medical directors, who oversee trial safety
Key numbers
- The FDA has granted both Regenerative Medicine Advanced Therapy and Fast Track designations to CT103A (equecabtagene autoleucel).
- In the key clinical study, called FUMANBA-1, the therapy demonstrated a 96% overall response rate among 101 evaluable patients with relapsed or refractory multiple myeloma.
- Of those patients, 95% achieved minimal residual disease (MRD) negativity, meaning traces of cancer were undetectable.
Quick answers
What happened in FDA Grants Myeloma Therapy Fast Track Designation?
The FDA has granted both Regenerative Medicine Advanced Therapy and Fast Track designations to CT103A (equecabtagene autoleucel). The designations are intended to accelerate the development and review of the therapy for relapsed or refractory multiple myeloma.
Why does FDA Grants Myeloma Therapy Fast Track Designation matter?
The therapy, equecabtagene autoleucel, is a CAR T-cell therapy, which involves extracting a patient's own T-cells (a type of immune cell) and genetically engineering them to recognize and attack cancer cells. These modified cells are then infused back into the patient. This specific therapy works by targeting the B-cell maturation antigen (BCMA), a protein found in high levels on the surface of multiple myeloma cells. In the key clinical study, called FUMANBA-1, the therapy demonstrated a 96% overall response rate among 101 evaluable patients with relapsed or refractory multiple myeloma. Of those patients, 95% achieved minimal residual disease (MRD) negativity, meaning traces of cancer were undetectable. The development of the Chimeric Antigen Receptor (the "CAR" in CAR-T) is a key role for computational biologists and bioinformaticians, who use large datasets to help identify unique protein targets on cancer cells to ensure the therapy is both effective and spares healthy tissue. The human testing of such therapies is managed by patient-facing professionals like clinical research coordinators and medical directors, who oversee trial safety
